The National Institute for Health and Care Excellence

500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable. Fezolinetant (also called Veoza and made by Astellas ...
The National Institute for Health and Care Excellence

Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 TA878 29 March 2023 26 February 2026 ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
National Institute for Health and Care Excellence

Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Indoor air quality at home

This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.
National Institute for Health and Care Excellence

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)

NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZeneca withdrew its evidence submission.
National Institute for Health and Care Excellence

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Dementia: assessment, management and support for people living with dementia and their carers

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living ...
National Institute for Health and Care Excellence

Acne vulgaris: management

This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical ...